Related Experiment Video
Updated: May 22, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Multimodal therapy of dyslipidemia]
Annett Stahn1, Markolf Hanefeld
1Zentrum für klinische Studien, Fiedlerstraße 34, Dresden, Germany. annett.stahn@gwtonline-zks.de
Clinical Research in Cardiology Supplements
|April 25, 2012
Summary
Dyslipidemia, characterized by high LDL cholesterol, low HDL cholesterol, and high triglycerides, contributes to cardiovascular events. Combination therapies with statins offer improved lipid management for combined dyslipidemia.
Area of Science:
- Cardiovascular Medicine
- Metabolic Disorders
- Pharmacology
Context:
- Atherogenesis involves complex lipid alterations, including elevated LDL-cholesterol, reduced HDL-cholesterol, and increased triglycerides, all linked to cardiovascular events.
- Dyslipidemia and metabolic syndrome are prevalent in Germany, necessitating effective treatment strategies.
- Statins are first-line treatments for dyslipidemia, but residual cardiovascular risk often remains.
Purpose:
- To highlight the importance of addressing hypertriglyceridemia and low HDL-cholesterol alongside LDL-cholesterol management.
- To review combination therapies for dyslipidemia that offer additional lipid-modifying benefits.
- To advocate for updated treatment guidelines incorporating management of mixed hyperlipoproteinemia.
Summary:
- Combined dyslipidemia, defined by low HDL-cholesterol, high triglycerides, and high LDL-cholesterol, poses a significant cardiovascular risk.
- While statins are standard, combination therapies involving Omega-3 fatty acids, nicotinic acid/laropiprant, or fibrates enhance lipid modification.
- These combinations provide additional benefits beyond statin monotherapy for patients with combined dyslipidemia.
Impact:
- Emphasizes the need for comprehensive lipid management beyond LDL-cholesterol reduction.
- Suggests that combination therapies are crucial for mitigating residual cardiovascular risk in dyslipidemia.
- Calls for guideline updates to include specific recommendations for mixed hyperlipoproteinemia treatment.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Overview of Lipid Metabolism
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:06Lipid Digestion
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:24Lipid Absorption
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...